Kesh Baboolal is a Professor of Medicine at The University of Queensland as well as a Consultant Nephrologist and General Physician at Royal Brisbane and Women’s Hospital. Prof Baboolal received his medical degree, MBBS, and doctorate degree, MD, (Doctor of Medicine) from The University of London.
Professor Baboolal’s research career started when he was awarded a National Kidney Research Fellowship and Juvenile Diabetes Foundation International Research Fellowship in the Division of Nephrology at Stanford University, California from 1992-1995. During this period he studied the role of the renin angiotensin system in progressive renal disease. The results of this research formed the basis of his postdoctoral MD degree, which was awarded by the University of London in 1996.
On returning to the UK in 1995 he was appointed a Lecturer in Renal Medicine at the University Hospital of Wales. In 1997 he was appointed a consultant in Nephrology, Transplantation and General Medicine. Throughout his clinical career he has continued his research interests. He has led a research group of post doctorate scientists, clinician trainees and MD candidates that has explored the role of the renin angiotensin system in human renal disease, molecular determinants of renal allograft nephropathy and the pathophysiology of new onset diabetes after transplantation. This work has included laboratory based, basic science research, clinical research involving complex physiology measurements in humans and multicentre international clinical trials. The outputs of this work have been published in International peer reviewed journals, presented at International Meetings as both invited speakers and as abstracts.
More recently Professor Baboolal has developed a research interest in healthcare economics related to renal disease and transplantation. In addition Prof Baboolal created an Operational Research Unit in collaboration with the School of Mathematics at Cardiff University. The basis of this work was to use operational sciences including modelling and forecasting to help optimise the design of clinical services and systems. The output of this work has been incorporated into National Institute of Clinical Excellence (NICE) technology assessments as well as clinical guidelines including:
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases : the official journal of the National Kidney Foundation 2002; 39(2 Suppl 1): S1-266. Baboolal K, Evans C, Moore RH: Incidence of end-stage renal disease in medically treated patients with severe bilateral atherosclerotic renovascular disease. Am J Kidney Dis 31:971–977, 1998
Renal Association Clinical Practice Guideline on anaemia of chronic kidney disease. Mikhail A, Shrivastava R, Richardson D. Nephron Clinical Practice 2011; 118 101-24.
National Institute of Clinical Effectiveness (NICE) appraisal of high cost immunosuppressant medications. Warrens AN, Baboolal K, Buist L, Dudley C, Koffman G, Lipkin G, Parrott N, Powis SH, Sweny P, Raftery M. Interpreting regulatory authority guidance on immunosuppressive therapy for renal transplantation: a response to the UK's National Institute for Clinical Excellence (NICE). Clin Nephrol. 69, 67-76, 2008.
The National Institute of Clinical Effectiveness (NICE) appraisal of anaemia therapies in patients with renal transplants Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento AL, Vincenti F. Prevalence and management of anaemia in renal transplant recipients: a European survey. Am J Transplant. 2003 Jul; 3(7): 835-45.
NICE evaluation: Kidney disease: peritoneal dialysis in the treatment of stage 5 chronic kidney disease Consultation, April 2011 Appendix B: Cost effectiveness of peritoneal dialysis provision. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting--a multicentre study. Nephrol Dial Transplant. 23, 1982-9, 2008
United Kingdom Guidelines Management of the failing kidney transplant. Compiled by a Working Party of The British Transplantation Society May 2014 www.bts.org.uk June 2014: Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353-8
University of York Centre for Reviews and Dissemination National Institute of Health Research; NHS Economic Evaluation Database - NHS EED - 31 March 2007 - Health Technology Assessments: Cost-effectiveness of sirolimus therapy with early cyclosporine withdrawal vs. long-term cyclosporine therapy in Australia: Baboolal K. A phase III prospective randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation. 2003; 75(8): 1404-8.
NICE - Health Technology Assessments: Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis 01 May 2010. Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting--a multicentre study. Nephrol Dial Transplant. 23, 1982-9, 2008
Williams JE: How efficient can an Emergency Unit be? A Perfect World Mode: Baboolal K: Griffiths JD; Knight VA; Nelson AV; Voake C; l. Emerg Med Journal doi:10.1136/emermed-2011-200101. 2012.